2026年半年度报告（英文版）

Full text of the 2026 Semi-annual Report of Huadong Medicine Co., Ltd.1Huadong Medicine Co., Ltd.2026 Semi-annual ReportAugust 27, 2026Full text of the 2026 Semi-annual Report of Huadong Medicine Co., Ltd.2Section I Important Notes, Contents and DefinitionsThe Board of Directors, directors, and senior manager of Huadong Medicine Co., Ltd.(hereinafter referred to as the "Company") hereby guarantee that the informationpresented in this report is authentic, accurate and complete and free of false records,misleading statements or material omissions, and shall undertake individual and joint legalliabilities.Lv Liang, the Company's legal representative and the officer in charge of accounting,and Qiu Renbo, head of accounting department (accounting manager) hereby declare thatthe financial statements in this semi-annual report are authentic, accurate, and complete.All directors have attended the Board of Directors meeting to review this semi-annualreport.The future plans, development strategies and other forward-looking statements in thissemi-annual report shall not be considered as a substantial commitment of the Company toinvestors. Investors and related parties should be fully aware of the risks, and understandthe differences between plans, forecasts and commitments.The risks the Company faces in operation including industry policy and product pricereduction risk, new drug R&D risk, investment and M&A risk and exchange ratefluctuation risk. For details, please refer to "X. Risks faced by the Company andcountermeasures" in "Section III. Management's Discussion and Analysis" in the Report.Therefore, investors are kindly reminded to pay attention to possible investment risks.The profit distribution plan deliberated and approved at the meeting of the Board ofDirectors is as follows: On the basis of 1,753,736,848.00 shares of the existing total sharecapital of the Company, a cash dividend of RMB 3.50 (tax inclusive) per 10 shares will bedistributed to all shareholders; a total of 0 bonus share (tax inclusive) will be issued; and nocapital reserves will be converted to increase the share capital. This 2026 semi-annual profitdistribution scheme falls within the scope authorized by the 2025 Annual Shareholders'Meeting resolution to the Board of Directors and does not require further approval by theShareholders' Meeting.Full text of the 2026 Semi-annual Report of Huadong Medicine Co., Ltd.3According to “Stock Listing Rules of the Shenzhen Stock Exchange”, if listedcompanies have both Chinese and other language version of public notice, they shouldensure the content of both versions are the same. In the case of discrepancy, the originalversion in Chinese shall prevail.Full text of the 2026 Semi-annual Report of Huadong Medicine Co., Ltd.4Table of ContentsSection I Important Notes, Contents and Definitions............................................................................................ 2Section II Company Profile and Key Financial Indicators.........